Hyperhidrosis

Aquavit Files Additional IND for DTX-024, a New Botulinum Toxin With Microchannel Technology™ for Palmar Hyperhidrosis

Retrieved on: 
Saturday, March 18, 2023
Neurotoxin, BA, Drug development, Columbia University Vagelos College of Physicians and Surgeons, University, Hyperhidrosis, Allergan, MBA, Uniform Securities Agent State Law Exam, Doctor of Philosophy, Aquavit, Harvard Medical School, Dermatology, Investment, Patient, Physician, Ophthalmology, FINRA, Axial, Drug discovery, Knowledge, Health, FDA, IND, Clostridium botulinum, Neurology, University of Oxford, Pharmaceutical industry, Management, MD

NEW YORK, March 18, 2023 /PRNewswire/ -- Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the treatment of palmar hyperhidrosis using its patented microchannel technology™.

Key Points: 
  • NEW YORK, March 18, 2023 /PRNewswire/ -- Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the treatment of palmar hyperhidrosis using its patented microchannel technology™.
  • Alongside Aquavit's biosimilar program for its botulinum toxin, this will be the first in the world, indicated for palmar hyperhidrosis, approved by FDA.
  • Aquavit has been investing in proprietary delivery technologies and related intellectual property for botulinum toxin.
  • This is a strategic move that puts them ahead of the curve in the fast-growing multi-billion-dollar botulinum toxin market.

Aquavit Files Two IND's For Its Botulinum Toxin With FDA

Retrieved on: 
Friday, March 17, 2023
AB toxin, Neurotoxin, Roa, Hyperhidrosis, Toxicity, Botulinum toxin, Physician, AAD, Knowledge, FDA, IND, Clostridium botulinum, Pharmaceutical industry, Canning, Dermatology, Aquavit

NEW YORK, March 17, 2023 /PRNewswire/ -- Aquavit Holdings, the exclusive licensee of Huons Global's Botulinum Toxin in the USA and Canada, will officially unveil the Aquatox™ program at the Annual American Academy of Dermatology - 2023, the world's largest dermatology conference scheduled from March 17-21, 2023, in New Orleans, LA.

Key Points: 
  • According to The Aesthetic Society and the Global Market Insights, botulinum toxin has been the #1 non-surgical aesthetic procedure since 1999 and is still growing rapidly with only 4 companies with approved botulinum toxin in the US.
  • With a projected CAGR of 7-9%, the global botulinum toxin market in 2026 is expected to be $8.9B.
  • For several years, Aquavit has been investing in its proprietary delivery technologies and related intellectual property for botulinum toxin.
  • We plan to introduce the most innovative botulinum toxin products, uplift and modernize the treatment paradigm" said Sobin Chang, CEO of Aquavit.

Candesant® Biomedical Announces Publication of Pilot Study Data on a Novel, Non-invasive Medical Device for the Reduction of Axillary Hyperhidrosis

Retrieved on: 
Tuesday, November 29, 2022
Hyperhidrosis, SAN, User experience, Perspiration, Food, Safety, Week, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Quality of life, Exocrine gland, MD, HDSS, Skin, TAT, GSP, Effectiveness, Medical device, Wool, Pharmaceutical industry, Silviculture

SAN FRANCISCO, Nov. 29, 2022 /PRNewswire/ -- Candesant Biomedical ("Candesant"), a clinical-stage company focused on the development of non-invasive treatments for primary hyperhidrosis (excessive sweating), today announced the publication of a pilot study showing that its investigational "TAT" (targeted alkali thermolysis) patch was well tolerated and reduced underarm sweating in patients with axillary hyperhidrosis. The report, "A Pilot Study of the Safety and Effectiveness of a Novel Device in Subjects with Axillary Hyperhidrosis," was published in the November print issue of the journal Dermatologic Surgery1.

Key Points: 
  • The study included 16 adults with Hyperhidrosis Disease Severity Scale (HDSS) scores of 3 or 4, indicating hyperhidrosis.
  • This novel, innovative, non-invasive solution is designed to reduce excessive sweating focused first on primary axillary hyperhidrosis (excessive underarm sweating).
  • Candesant Biomedical is a clinical stage company focused on the development of non-invasive treatments for hyperhidrosis or excessive sweating.
  • Candesant is developing a product utilizing its patented targeted alkali thermolysis (TAT) technology, with the lead indication for primary axillary hyperhidrosis, with future potential indications including facial hyperhidrosis, palmar hyperhidrosis, and plantar hyperhidrosis.

Sensus Healthcare Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 3, 2022
ROI, System, Company, Growth, Sale, GAAP, Finasteride, GLOBE, Tropical Storm Ian, Method, Conference, EBITDA, Vision, Tax, COVID-19, Nasdaq, Marketing, Income, EPS, Attention, Research, Adjustment, Conference call, Toxin (comics), TDI, Epidermis, Hyperhidrosis, SRT, Dermatology, Advertising, Depreciation, Patient, Pain, Medical imaging, Video game, Security (finance), Pharmaceutical industry, Bookkeeping

BOCA RATON, Fla., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three and nine months ended September 30, 2022.

Key Points: 
  • Revenues for the third quarter of 2022 were $9.0 million, compared with $5.5 million for the third quarter of 2021.
  • Cost of sales for the third quarter of 2022 was $3.1 million, compared with $2.3 million for the prior-year quarter.
  • Selling and marketing expense for the third quarter of 2022 was $1.8 million, compared with $1.2 million for the third quarter of 2021.
  • Adjusted EBITDA for the third quarter of 2022 was $2.3 million, compared with $0.5 million for the third quarter of 2021.

Breaking the Stigma of Excessive Sweating During Hyperhidrosis Awareness Month

Retrieved on: 
Tuesday, November 1, 2022
Population, Efficiency, Social stigma, Research, Finger, View, Health care, Swelling, Friends, CME, Skin, Clothing, Hyperhidrosis, CEO, Perspiration, Jaw, Family, Psoriasis, Oil, Shame, Embarrassment, Patient, Multimedia, Cyst, Hypertrichosis, Itchy, Pimple, Awareness, Dizziness, Earwax, Risk, Physician, Bacteria, Continuing medical education, Bleeding, Education, Hearing loss, Ear canal, Diagnosis, Blog, Pain, Acne, News, YouTube, Itch, Anxiety, Eyelash, Social media, Irritation, Quality of life, Depression, Pharmaceutical industry, Medical device, Cosmetics, Dentistry, Online shopping, IHH (Turkish NGO)

CENTER VALLEY, Pa., Nov. 1, 2022 /PRNewswire/ -- Today marks the beginning of Hyperhidrosis Awareness Month and the International Hyperhidrosis Society (IHhS) is committed to raising awareness of this medical condition that affects 365 million people worldwide, of which 27% of adults go undiagnosed. In the United States alone, more than 15 million Americans have hyperhidrosis (approximately 5% of the population), but many of those dealing with the condition fail to recognize it as a medical issue and only 51% discuss it with their physicians.

Key Points: 
  • While sweating is a normal, necessary part of human function, hyperhidrosis sufferers experience excessive and uncontrollable perspiration that interferes with daily functioning, negatively impacting their quality of life.
  • "Our organization's goal is to is educate sufferers, provide support and show them they don't have to live with excessive sweating as hyperhidrosis can be effectively treated."
  • This November during Hyperhidrosis Awareness Month, the IHhS is especially committed to spreading the word about hyperhidrosis to help destigmatize, educate and effectively treat the condition.
  • Attendees will learn best practices in hyperhidrosis diagnosis and management as well as the latest research related to excessive sweating.

The Best You® Acquires Bay Street Salon and Spa

Retrieved on: 
Tuesday, October 18, 2022
Surgery, Health, Oncology, Physician, PRP, Hyperhidrosis, Skin care, Ontario Health Insurance Plan, Dermatology, Family, Fat removal procedures, TBY, Partnership, Knowledge, You Wanted the Best, You Got the Best!!, Breast augmentation, Friends, Acquisition, Onychomycosis, Pedicure, Blepharoplasty, Leadership, Platelet-rich plasma, Hair removal, Bay Street, OHIP, Mesotherapy, Acne, Ownership, Skin cancer, United Counties of Prescott and Russell, Beauty salon, General store, National Capital Region (Canada), Embrun

The Best You (TBY), a long-standing group of medical aesthetic clinics in Ontario, today announced that it has completed the acquisition of the Bay Street Salon and Spa in Embrun, Ontario (Bay Street).

Key Points: 
  • The Best You (TBY), a long-standing group of medical aesthetic clinics in Ontario, today announced that it has completed the acquisition of the Bay Street Salon and Spa in Embrun, Ontario (Bay Street).
  • The Bay Street Salon and Spa, located 20 minutes from the outskirts of Ottawa, complements TBYs current offerings.
  • Bay Street is a family-owned and operated salon and spa, offering massage therapy, hair styling services as well as laser treatments for acne, onychomycosis and wart removal, vascular treatments, laser hair removal, and CoolSculpting.
  • With the addition of Bay Street Salon and Spa to its portfolio of companies, TBY will expand its service offerings across the Greater Ottawa area and continue to provide excellent client service based on the knowledge, expertise, and leadership of the team at Bay Street.

Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly

Retrieved on: 
Thursday, October 13, 2022
SAN, Hyperhidrosis, Sleep apnea, Therapy, Glucose, Securities Act of 1933, ACTH, Paresthesia, Hormone, Arthritis, Carcinoid syndrome, SST2, Serum, Marketing, Needle, Lipid metabolism, Medication, GLOBE, Clinical trial, FDA, Time, Adenoma, Congenital adrenal hyperplasia, Acromegaly, Pituitary adenoma, ULN, Vocal cords, Research, Annual report, Form 10-K, Growth hormone, Headache, Pain, Securities Exchange Act of 1934, Injection, Intellectual property, Arthralgia, Degenerative disease, Physician, Drug Quality and Security Act, Fatigue, SEC, Carpal tunnel syndrome, Congenital hyperinsulinism, Patient, Wilms' tumor, Nasdaq, Human, Drug discovery, Safety, Liver, Heart, COVID-19, GH, Octreotide, Pharmaceutical industry

PATHFNDR-1 is one of two ongoing, placebo-controlled Phase 3 studies evaluating the safety and efficacy of once-daily oral paltusotine in acromegaly patients.

Key Points: 
  • PATHFNDR-1 is one of two ongoing, placebo-controlled Phase 3 studies evaluating the safety and efficacy of once-daily oral paltusotine in acromegaly patients.
  • The Phase 3 PATHFNDR-2 studys enrollment is ongoing and topline results are expected in the fourth quarter of 2023.
  • We would like to thank study participants and clinical research professionals for their interest and contributions to the PATHFNDR-1 study.
  • In Phase 2 studies, paltusotine maintained IGF-1 levels in acromegaly patients who switched from injectable depot medications to once-daily oral paltusotine.

Candesant® Biomedical Launches SweatTech™ Initiative to Educate on the Evolution of Treatments for Hyperhidrosis (Excessive Sweating)

Retrieved on: 
Friday, October 7, 2022
People, Aurora, FAAD, Hyperhidrosis, Review, Perspiration, Regulation of tobacco by the U.S. Food and Drug Administration, Society, Patient, Research, TAT, Technology, Food, Exocrine gland, MD, CO, 1,000,000, CEO, Awareness, Injection, ASDS, Solution, Wool, Medical device

SAN FRANCISCO, Oct. 7, 2022 /PRNewswire/ -- Candesant Biomedical ("Candesant"), a clinical stage company focused on the development of non-invasive treatments for primary hyperhidrosis (excessive sweating), today announced the "SweatTech Initiative" to raise awareness of the significant impact of excessive sweating, educate on how treatments have evolved over the decades, and demonstrate the ongoing need for more modern treatments. The initiative launched at the American Society for Dermatologic Surgery Annual Meeting, taking place from October 6-10 in Denver, CO.

Key Points: 
  • While approaches to control hyperhidrosis have evolved with technological advances, some treatments involve injections or surgery, or cause staining on clothes," stated Niquette Hunt, President and CEO of Candesant.
  • Candesant is developing a novel, innovative, non-invasive solution designed to reduce excessive sweating focused first on primary axillary hyperhidrosis (excessive underarm sweating).
  • Candesant Biomedical is a clinical stage company focused on the development of non-invasive treatments for hyperhidrosis or excessive sweating.
  • Candesant is developing several products utilizing their targeted alkali thermolysis (TAT) technology, with future target indications for axillary hyperhidrosis, palmar hyperhidrosis, plantar hyperhidrosis, and facial hyperhidrosis.

Launch Of Aesthetic Medical Boutique Brand Profile MD Announced

Retrieved on: 
Monday, September 19, 2022
Health, Botulinum toxin, IV, Diet, MD, Plastic, Patient, Radio, Neurotoxin, Internal medicine, Preventive healthcare, Flex, Hyperhidrosis, Bariatrics, Pharmaceutical industry, Sculptra

SEVERNA PARK, Md., Sept. 19, 2022 /PRNewswire/ -- MD-based Profile MD has just announced the launch of their new aesthetic medical brand at 484A Ritchie Hwy, Severna Park, MD 21146.

Key Points: 
  • SEVERNA PARK, Md., Sept. 19, 2022 /PRNewswire/ -- MD-based Profile MD has just announced the launch of their new aesthetic medical brand at 484A Ritchie Hwy, Severna Park, MD 21146.
  • This new medical boutique will provide patients in the Maryland area with holistic care that encompasses aesthetic treatments, skin rejuvenation, medical weight loss, and more.
  • Profile MD will merge the procedures offered by the Laser Center of Maryland with an experienced team that supports its evolving mission.
  • The medical service clinicians will be expanding beyond medical aesthetics, non-invasive and minimally invasive procedures to prioritize wellness.

How Much Does Botox Cost In Seattle?

Retrieved on: 
Thursday, September 8, 2022
Breast augmentation, Google, Ageing, Patient, BOTOX, Hyperhidrosis, Perspiration, Injection, Migraine, Taxicab, Dentistry

SEATTLE, Sept. 8, 2022 /PRNewswire/ -- Everyone wants a good deal, especially when it comes to an investment such as Botox injections. Many people will offer cheap Botox injections, but only Seattle Plastic Surgery offers low cost Botox with highly qualified injectors with years of experience. At Seattle Plastic Surgery, you can expect personalized treatment with some of the top Botox injectors in Seattle.

Key Points: 
  • Many people will offer cheap Botox injections, but only Seattle Plastic Surgery offers low cost Botox with highly qualified injectors with years of experience.
  • At Seattle Plastic Surgery, you can expect personalized treatment with some of the top Botox injectors in Seattle.
  • However, they also perform facial slimming Botox and certain medical Botox treatments such as injections for migraines or hyperhidrosis.
  • The cost of BOTOX at Seattle Plastic Surgery is 20 units for $219 and 30 units for $299.